Teknova(US:TKNO) Globenewswire·2025-11-06 21:01Core Insights - Alpha Teknova, Inc. reported total revenue of $10.5 million for Q3 2025, reflecting a 9% increase from $9.6 million in Q3 2024, marking five consecutive quarters of year-over-year revenue growth [1][6][9] - The company reaffirms its 2025 revenue guidance, expecting total revenue between $39 million and $42 million [1][12] Financial Performance - Revenue Breakdown: - Lab Essentials revenue was $8.3 million, up 16% from $7.2 million in Q3 2024 - Clinical Solutions revenue was $1.7 million, down 13% from $2.0 million in Q3 2024 [4][6] - Gross profit for Q3 2025 was $3.2 million, with a gross margin of 30.7%, significantly improved from $0.1 million and 0.9% in Q3 2024 [7] - Operating expenses decreased to $7.2 million in Q3 2025 from $7.5 million in Q3 2024, primarily due to reduced general and administrative spending [8] Cash Flow and Losses - Net loss for Q3 2025 was $4.3 million, or negative $0.08 per diluted share, an improvement from a net loss of $7.6 million, or negative $0.15 per diluted share, in Q3 2024 [10][22] - Adjusted EBITDA for Q3 2025 was negative $1.6 million, an improvement from negative $5.0 million in Q3 2024 [11][27] - Free Cash Outflow remained consistent at $2.4 million for both Q3 2025 and Q3 2024 [11][27] Balance Sheet Highlights - As of September 30, 2025, total cash and short-term investments were $22.1 million, with total borrowings of $13.2 million [9][23] - Total assets decreased to $107.6 million from $118.8 million as of December 31, 2024 [24] Market Position and Outlook - The company continues to see growth in its Clinical Solutions customer base, which, along with a diverse product portfolio, positions it for sustainable growth [2] - Teknova anticipates Free Cash Outflow of less than $12 million for the fiscal year 2025 [12]